Analytic study of clinical presentation of intracranial space-occupying lesions in adult patients

Bashir A. Soomro  
Neuro Clinic and Care, Karachi, Pakistan.

Sameen Khalid  
Ziauddin Hospital Karachi

Shafag Alvi  
Neuro Clinic and Care, Karachi, Pakistan.

Follow this and additional works at: http://ecommons.aku.edu/pjns

Part of the Neurology Commons

Recommended Citation
Available at: http://ecommons.aku.edu/pjns/vol9/iss3/2
ANALYTIC STUDY OF CLINICAL PRESENTATION OF INTRACRANIAL SPACE-OCCUPYING LESIONS IN ADULT PATIENTS

Bashir A. Soomro¹, Sameen Khalid², Shafaq Alvi¹
¹ Neuro Clinic and Care, Karachi, Pakistan.
² Ziauddin Hospital, Shahrah-e-Ghalib, Karachi, Pakistan

Correspondence to: Bashir A. Soomro, 43/ II Zulfiqar Street No: 03, Phase VIII DHA, Karachi. Postal Code: 75500. Email: basoomro@gmail.com
Date of submission: July 5, 2014, Date of revision: September 10, 2014, Date of acceptance: September 22, 2014

ABSTRACT

Background: Intracranial space-occupying lesions can be caused by a variety of disease processes, ranging from neoplasms to non-neoplastic lesions including hematomas, abscesses and vascular malformations. This article provides an overview of varied clinical presentations of patients with intracranial space-occupying lesions.

Methods: A total of 200 cases of intracranial space-occupying lesions presenting at Neuro Clinic and Care were retrospectively analyzed. Adult patients from all age groups and both genders were included in this study.

Results: 165 patients (82.5%) had neoplastic lesions while 35 (17.5%) had non-neoplastic lesions. Metastatic lesions from primary tumor elsewhere in the body comprised the most common group with 81 cases (40.5%), followed by meningiomas with 27 cases (13.5%). Males were affected slightly more than females (1:0.8). The most common presenting symptom was headache in 87 patients (43.5%), followed by focal symptoms such as numbness, tingling or weakness being present in 80 (40%) and seizures observed in 65 (32.5%).

Conclusion: The study reviews the wide range of symptoms the patients with intracranial space-occupying lesions present with, the most common being headache, followed by focal symptoms such as numbness, tingling or weakness, seizures and vomiting. Knowledge of these typical as well as atypical patterns of clinical presentation can aid physicians in timely detection and prompt application of diagnostic and therapeutic modalities.

Key Words: Intracranial space-occupying lesions, Primary brain tumors, Clinical presentation.

ORIGINAL ARTICLE

INTRODUCTION

The term “intracranial space-occupying lesion” refers to neoplasms as well as non-neoplastic lesions. Neoplasms may be benign or malignant and primary or metastatic. Non-neoplastic lesions include hematomas, cerebral abscesses including Toxoplasmosis, cysts including arachnoid cysts, colloid cysts, dermoid cysts, epidermoid cysts, vascular malformations and inflammatory or parasitic masses such as cerebral Amoebiosis and cystercerosis within cranial cavity. Primary malignant tumors of the central nervous system (CNS) account for approximately 2% of all the primary tumors of the human body. Considerable regional and racial variations play a role in the difference in the incidence and pattern of intracranial neoplastic space-occupying lesions (SOL) throughout the world. In most studies reported from Asian countries, brain tumors occurred mostly during 4th decade of life while in Western countries, during 5th and 6th decades of life. Incidence of brain tumors in the U.S. is 10 per 100,000 person-years, with a male-female ratio of 6:4. Primary brain tumors are classified on the basis of their histological appearance and cellular origin. Primary brain tumors can be classified as gliomas or non-gliomas. Gliomas account for >80% of primary brain tumors and include astrocytomas, oligodendrogliomas, ependymomas and mixed oligodendrogial and astrocytic tumors. Non-gliomas comprise of benign tumors such as meningiomas and pituitary adenomas as well as malignant tumors such as medulloblastomas, primary CNS lymphomas and CNS germ cell tumors. The most common benign brain tumors are meningiomas, comprising about 20% of primary brain tumors. Astrocytomas including Glioblastoma multiforme (GBM) are the most common malignant brain tumors. Almost half of the brain tumors are primary and the remaining are metastases that have originated outside the CNS. Brain metastases are more common than primary malignant brain tumors and are usually multiple. The most common tumor metastasizing to brain is carcinoma lung followed by carcinoma breast, colonic carcinoma and malignant melanoma. Patients with intracranial space-occupying lesions can present with signs and symptoms that can be generalized or focal. Focal symptoms are due to localized brain damage and presentation may indicate location of lesion. These symptoms include weakness, somatosensory loss, visual...
<table>
<thead>
<tr>
<th>Table 1: Presenting Symptoms &amp; Signs in Patients with Intracranial Space-Occupying Lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Generalized Signs &amp; Symptoms</strong></td>
</tr>
<tr>
<td>Headache</td>
</tr>
<tr>
<td>Nausea, Vomiting</td>
</tr>
<tr>
<td>Seizures</td>
</tr>
<tr>
<td>Personality changes</td>
</tr>
<tr>
<td>Change in mental status</td>
</tr>
<tr>
<td>Motor deficits</td>
</tr>
<tr>
<td>Sensory deficits</td>
</tr>
<tr>
<td>Papilledema</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Frontal Lobe:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personality changes</td>
</tr>
<tr>
<td>Hemiparesis</td>
</tr>
<tr>
<td>Expressive aphasia</td>
</tr>
<tr>
<td>Anosmia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Parietal Lobe:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spatial disorientation</td>
</tr>
<tr>
<td>Hemisensory loss</td>
</tr>
<tr>
<td>Receptive aphasia</td>
</tr>
<tr>
<td>Hemianopia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Occipital Lobe:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contralateral hemianopia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cerebellum:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ataxia</td>
</tr>
<tr>
<td>Dysmetria</td>
</tr>
<tr>
<td>Nystagmus</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cerebello-pontine angle (Acoustic neuroma):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ipsilateral deafness</td>
</tr>
<tr>
<td>Tinnitus</td>
</tr>
<tr>
<td>Nystagmus</td>
</tr>
<tr>
<td>Ipsilateral cerebellar signs</td>
</tr>
<tr>
<td>Facial and Trigeminal palsies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pituitary tumors: Endocrine symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visual defects</td>
</tr>
</tbody>
</table>
loss or aphasia and tend to occur in the initial stages of disease. Generalized symptoms occur as the tumor size increases and/or when intracranial pressure (ICP) rises. These symptoms include headache, nausea, vomiting, seizures, neurocognitive symptoms, personality changes and false localizing signs \(^{(3,15-18)}\). Large lesions in some locations in the brain (silent regions) may remain relatively quiescent while a small lesion in dominant hemisphere may drastically impair speech. A space-occupying lesion in CNS may infiltrate and destroy important structures. It can impair cerebrospinal fluid (CSF) flow causing hydrocephalus or it can induce formation of new blood vessels leading to vasogenic edema. In rare instances, intracranial lesions can manifest with unusual symptoms that range from syncopal attacks, vertigo, and vestibular neuritis to local symptoms such as sensory seizures \(^{(15)}\), dermalomal hypoesthesia, ulnar neuropathy \(^{(15)}\), trigeminal neuralgia \(^{(19)}\) and even Parkinsonism \(^{(20)}\). Physicians could err in their diagnosis and in formulating treatment plans because of these unusual presentations.

This study aims to enhance the knowledge regarding the varied clinical presentations of intracranial space-occupying lesions in adult patients to allow early diagnosis and prompt treatment. To the best of our knowledge, current study is one of the few studies conducted in Pakistan regarding the frequency of intracranial space-occupying lesions and the first study from Pakistan demonstrating the spectrum of clinical presentation of intracranial space-occupying lesions in adults.

**METHODOLOGY**

The study was carried out retrospectively in which data from a total of 200 patients with intracranial space-occupying lesions; having been collected over a period of 14 years was reviewed during four months from April 2014 to August 2014 at Neuro Clinic and Care, Karachi, Pakistan. Adult patients from all ages and both genders were included in the study. Diagnosis of intracranial space-occupying lesion was made by either histological examination (biopsy) or radiological examination (computed tomography or magnetic resonance imaging). Data was entered and saved onto SPSS version 20. Before analyzing; data was checked and corrected for any possible error in data entry. Separate frequency and valid percentages were calculated for main categorical variables.

**RESULTS**

A total of 200 cases of intracranial space-occupying lesions presenting at Neuro Clinic and Care were retrospectively analyzed. Adult patients from all age groups and both genders were included in this study. The mean age of respondents was 50 (SD +/- 2) years. Male patients constituted 56% (111) and females were 45% (89), giving a male/female ratio of 1:0.8. Figure 1 shows that out of 200 cases of intracranial space-occupying lesions, 82.5% (n=165) were neoplasms, most common of which were brain metastases (40.5%, n=81). Meningiomas ranked second with 27 cases (13.5%) while undifferentiated gliomas (12%, n=24) were third in frequency. Astrocytomas accounted for 9.5% (n=19) cases and oligodendroglialomas were 3% (n=6). Acoustic neuromas (Schwannomas) and pituitary tumors each constituted 2% (n=4) of the lesions. Among the 17.5% (n=35) cases of non-neoplastic lesions, the most common was tuberculosis (11%, n=22) followed by brain abscesses (2%, n=4), neurocysticercosis and toxoplasmosis, each being 0.5% (n=1). Fungal granulomas, arteriovenous malformations and nasopharyngeal mass eroding base of skull comprised 3.5% of cases (n=7). As depicted in Table 2, of all the 200 cases of intracranial space-occupying lesions, the most common clinical presentation was headache (43.5%, n=87) which was characterized in most cases as constant, progressive over a period of weeks or months and moderate to severe in intensity. Focal symptoms such as numbness, tingling and weakness occurred in 40% of cases (n=80). Seizures ranked third in frequency with 32.5% of cases (n=65) and vomiting occurred in 27.5% of cases (n=55). Speech deficit and loss of vision or diplopia ranked fifth and sixth in frequency with 15% (n=30) and 13.5% (n=27) cases respectively. 12% of the patients (n=24) had gait disturbances while 10.5% (n=21) had dizziness. Urine incontinence was found in 7% of the patients (n=14). Progressive decline in cognitive functions occurred in 6.5% (n=13) patients and personality changes were found in 4% (n=8) of the cases. 3.5% of the cases (of acoustic neuroma); (n=7) had hearing deficits while only 1% (n=2) had loss of smell. None of the patients was found to have loss of taste. Other symptoms such as drowsiness, unconsciousness, repeated falls, tinnitus, weight loss, neck pain, dysphagia, generalized weakness and fever occurred in 52.5% of the patients (n=105). While evaluating the patients, motor deficits were found to be the most common presenting sign (Table 3) with 92.5% of the patients (n=185) showing an increase in tone and/or a decrease in power, demonstrating signs of upper motor neuron lesions. Gait disturbances including heel and toe walking were found in more than half of the cases (52.5%, n=105). Sensory impairment in pain, touch, temperature and/or deep pressure sensations that evaluates integrity of anterior/lateral columns was found in 2.5% of the patients (n=5) while sensory impairment in position and vibration sensations evaluating
Figure 1: Distribution of 200 cases of intracranial space-occupying lesions

The integrity of posterior column occurred in 14% (n=28). Cerebellar signs such as nystagmus, positive finger-nose and heel-shin tests and impaired rapid alternating movements were present in 24% (n=48). Level of consciousness was impaired in a quarter of the patients (25%, n=50) with 27.5% of the patients (n=55) not oriented to person, place and/or time. Memory impairment was found in 36.5% of the cases (n=73) and higher cortical functions that were evaluated by serial sevens and calculations were also impaired in 36.5% (n=73). Speech impairment was present in 13.5% of the cases (n=27). Loss of smell occurred in 1.5% (n=3). Cranial nerve II impairment demonstrated by compromised visual acuity, visual fields and by fundoscopic examination showing papilledema was found in 32% (n=64). Pupillary response and extraocular muscle movements were impaired in 12% of the patients (n=24). Facial sensations, corneal reflex and Masseter’s bulk and power (demonstrating integrity of cranial nerve V) were impaired in 2.5% (n=5) while cranial nerve VII evaluated by checking facial movements was impaired in 24.5% (n=49). Cranial nerve VIII was evaluated by hearing tests (Rinne and Weber) and was found to be impaired in 6.5% (n=13). Gag reflex assessing cranial nerves IX and X was absent in 6% of the cases (n=12). Only 2 patients (1%) had impaired active and passive neck movements showing compromised function of cranial nerve XI while tongue mass and movements demonstrating intactness of cranial nerve XII were impaired in 1.5% of the patients (n=3).

DISCUSSION

Both neoplastic and non-neoplastic intracranial space-occupying lesions share features of clinical presentation. In a study involving 100 cases of intracranial space occupying lesions conducted in Lahore, Pakistan,(1) neoplastic lesions comprised 89% of the cases while non-neoplastic lesions were reported to be 11%, which gives a similar proportion as in our study of 200 cases comprising of 82.5% neoplastic and 17.5% non-neoplastic lesions. Males were affected slightly more than females in their study giving a sex ratio of 1.7: 1, which correlates with the results of our study.
Headache, the most common presenting symptom in our study, occurred in 43.5% of the patients. Buckner et al. pointed out that the new onset of headache that is constant, progressive, severe, especially worse in the morning and occurs in association with nausea, vomiting or focal neurological deficits is more characteristic of an intracranial space-occupying lesion (2). In patients with pre-existing headaches, a change in the prior headache pattern or an increase in their frequency or intensity suggests presence of an intracranial mass (2, 21). Headache often occurred in association with other symptoms, including nausea and vomiting (27.5% of the patients), visual disturbances (13.5%), gait disturbances (12%), and dizziness (10.5%). In a retrospective study of 111 patients conducted by Forsyth and Posner, headaches were present in 48% of the patients with primary and metastatic brain tumors, which gives a similar proportion as in our study. Most headaches (77%) were tension-type headache while only some were migraine-type (9%) (21). Some locations are more likely to produce headaches, for example, infratentorial and intraventricular tumors were found to cause headache more frequently than a supratentorial tumor, as a result of impaired CSF flow causing hydrocephalus and raised ICP resulting in midline shift (22, 23). Rapidly growing tumors are more often associated with headache than slow-growing tumors. A study that analyzed signs and symptoms of 279 patients with brain tumors pointed out that in only 1/3rd of the patients the site of the tumor coincided with the lateralization of headache (23). In our study, seizure activity occurred in 32.5% of the patients which is similar in frequency to a study conducted in US by Chandana and Movva (3). Seizure activity has been reported in various studies to be more common in patients with low-grade gliomas (2, 3, 15, 16). Location of the space-occupying lesion:

Table 2: Frequency of different clinical symptoms of intracranial space-occupying lesions

<table>
<thead>
<tr>
<th>SYMPTOMS</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>87</td>
<td>43.5%</td>
</tr>
<tr>
<td>Seizures</td>
<td>65</td>
<td>32.5%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>55</td>
<td>27.5%</td>
</tr>
<tr>
<td>Dizziness</td>
<td>21</td>
<td>10.5%</td>
</tr>
<tr>
<td>Progressive decline in cognitive functions</td>
<td>13</td>
<td>6.5%</td>
</tr>
<tr>
<td>Speech deficit</td>
<td>30</td>
<td>15%</td>
</tr>
<tr>
<td>Personality changes</td>
<td>8</td>
<td>4%</td>
</tr>
<tr>
<td>Focal signs/symptoms</td>
<td>80</td>
<td>40%</td>
</tr>
<tr>
<td>Loss of smell</td>
<td>2</td>
<td>1%</td>
</tr>
<tr>
<td>Loss of vision / Diplopia</td>
<td>27</td>
<td>13.5%</td>
</tr>
<tr>
<td>Loss of taste</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>Hearing deficits</td>
<td>7</td>
<td>3.5%</td>
</tr>
<tr>
<td>Gait disturbances</td>
<td>24</td>
<td>12%</td>
</tr>
<tr>
<td>Urine incontinence</td>
<td>14</td>
<td>7%</td>
</tr>
<tr>
<td>Others (drowsiness, disorientation, unconsciousness, repeated falls, tinnitus, weight loss, neck pain, dysphagia, generalized weakness, fever)</td>
<td>105</td>
<td>52.5%</td>
</tr>
</tbody>
</table>

Table 3: Frequency of different clinical signs of intracranial space-occupying lesions

<table>
<thead>
<tr>
<th>SIGNS</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impaired consciousness</td>
<td>50</td>
<td>25%</td>
</tr>
<tr>
<td>Not oriented to person, place and/or time</td>
<td>55</td>
<td>27.5%</td>
</tr>
<tr>
<td>Impaired memory</td>
<td>73</td>
<td>36.5%</td>
</tr>
<tr>
<td>Impaired higher cortical functions</td>
<td>73</td>
<td>36.5%</td>
</tr>
<tr>
<td>Impaired speech</td>
<td>27</td>
<td>13.5%</td>
</tr>
<tr>
<td>CN I: Impaired sense of Smell</td>
<td>3</td>
<td>1.5%</td>
</tr>
<tr>
<td>CN II: Papilledema, abnormalities in visual acuity and visual fields</td>
<td>64</td>
<td>32%</td>
</tr>
<tr>
<td>CN III, IV, VI: Restricted Extraocular muscle movements and Abnormal pupillary reflexes</td>
<td>24</td>
<td>12%</td>
</tr>
<tr>
<td>CN V: Facial sensation, corneal reflex, masseter’s bulk &amp; power impairment</td>
<td>5</td>
<td>2.5%</td>
</tr>
<tr>
<td>CN VII: Impaired Facial movements</td>
<td>49</td>
<td>25%</td>
</tr>
<tr>
<td>CN VIII: Hearing Abnormalities (tested Weber and Rinne)</td>
<td>13</td>
<td>6.5%</td>
</tr>
<tr>
<td>CN IX, X: Absent gag reflex</td>
<td>12</td>
<td>6%</td>
</tr>
<tr>
<td>CN XI: Impaired neck movements</td>
<td>2</td>
<td>1%</td>
</tr>
<tr>
<td>CN XII: Abnormalities of tongue mass and movements</td>
<td>3</td>
<td>1.5%</td>
</tr>
<tr>
<td>Motor deficits</td>
<td>185</td>
<td>92.5%</td>
</tr>
<tr>
<td>Sensory deficits—Anterior/Lateral column (pain, temperature, touch, deep pressure)</td>
<td>5</td>
<td>2.5%</td>
</tr>
<tr>
<td>Sensory deficits—Posterior column (position, vibration)</td>
<td>28</td>
<td>14%</td>
</tr>
<tr>
<td>Cerebellar signs</td>
<td>48</td>
<td>24%</td>
</tr>
<tr>
<td>Gait disturbances</td>
<td>105</td>
<td>52.5%</td>
</tr>
</tbody>
</table>
pying lesion may determine the type of seizure and associated neurologic symptoms. Progressive decline in cognitive functions as the presenting symptom in patients with intracranial space-occupying lesions occurred in 6.5%. Cognitive dysfunction includes changes in memory, orientation, higher cortical functions and speech. Personality changes were reported in 4% of the patients. According to Chandana and Movva, symptoms of cognitive dysfunction are more likely to herald the presence of an intracranial lesion in dominant hemisphere than in non-dominant hemisphere (3). Focal symptoms including motor and sensory deficits such as numbness, tingling and weakness was found in 40% of the patients. Patients with intracranial space-occupying lesions can manifest with unusual symptoms ranging from syncope attacks, vertigo, vestibular neuritis, dermalatomal hypotensia, psychiatric symptoms to local signs such as sensory seizures and entrapment neuropathy. Our study demonstrated some interesting symptoms that patients with intracranial SOLs may present with. These include loss of smell (1%), hearing deficits (3.5%) and speech deficits (15%). Similarly, trigeminal neuralgia has been reported as the initial manifestation of temporal glioma. The patients presented with episodic, lancinating facial pain. These intracranial supratentorial gliomas occurred especially in young patients.19 In our study, functions of trigeminal nerve such as facial sensations, corneal reflex and Masseter's bulk and power were impaired in 2.5% (n=5). Because Glioblastoma Multiforme (GBM) is the most common primary brain tumor, it has presented in a number of unusual ways such as unlar neuropahty, vertigo and syncopal attacks (16); musogenic epilepsy and reflex epilepsy (24-26), pseudo-foreign language syndrome (27, 28), unusual pain syndrome (28) and unusual personality changes e.g. hypersexuality and anorexia nervosa (27,29,30). GBM of the pineal gland (which is extremely rare at this location), has been reported to present with hydrocephalus due to compression of the aqueduct of Sylvius and visual disturbances e.g. horizontal nystagmus and CN VI palsy (32). Parkinsonism has also been described as a presenting feature of intracranial space-occupying lesions. Tumors that infiltrate or compress striatum or substantia nigra may present with features of Parkinsonism. Meningiomas are the most common histological type that can present with it, particularly those with a supratentorial localization (20). Intracerebral schwannomas, in our study, make up 2% of all intracranial space-occupying lesions. These tumors commonly presented with seizures, headache, nystagmus, tinnitus, hearing loss, facial or trigeminal palsies. In rare instances, this tumor has been reported to present as classic temporal lobe epilepsy (33-36). Intracranial space-occupying lesions can also present with central pain. Patients with meningioma, low-grade astrocytoma, brain abscess or arteriovenous malformation causing central pain due to compression of parietal cortex have been reported in literature. Thalamic tumors have also been reported as a cause of central pain (37).

REFERENCES